Option chain shows key data for Bright Minds Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bright Minds Biosciences.

Bright Minds Biosciences (NASDAQ:DRUG) Stock, Option Chain

Bright Minds Biosciences

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Epilepsy drugs

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

DRUG

Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite limited clinical data.

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

BCTX

RXRX


Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and

Biotechs on the Brink: 2 Stocks With Huge Potential

Analysts

Pre-Market Outlook

Markets

ELVA

EXOD

This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences Inc

DRUG FREE SOLUTION INC by Drug Free Solution Inc.

Drug Free Solution Inc

Drugs Made In America Acquisition Corp. - Ordinary Shares

Drugs Made In America Acquisition Corp

Drugs Made In America Acquisition Corp. - Units

Drugs Made In America Acquisition Corp. - Rights

Press Releases

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

Management

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Comments

Bright Minds Biosciences

Bright Minds Biosciences (DRUG) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell